570 Participants NeededMy employer runs this trial

Fel d 1 Monoclonal Antibodies for Allergic Eye

CT
Overseen ByClinical Trials Administrator
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Regeneron Pharmaceuticals
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs".

The aim of the study is to see what side effects freneslerbart, mevonlerbart, and REGN-2Cat may have and if they help reduce eye allergy symptoms caused by cat hair/dander compared with a placebo.

The study is looking at several other research questions, including:

* How much study drug is in the blood at different times

* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

* How long the study drug effect lasts

Who Is on the Research Team?

CT

Clinical Trial Management

Principal Investigator

Regeneron Pharmaceuticals

Are You a Good Fit for This Trial?

This trial is for adults and children (8 years and older) who have allergic eye symptoms caused by cats. Participants must test positive for cat allergy on skin and blood tests.

Inclusion Criteria

I have tested positive for a cat allergy.
I meet the main requirements for this study.
I am in the required age group for this study part.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Freneslerbart
  • Mevonlerbart
  • REGN-2Cat

Trial Overview

The study is testing two new medicines, freneslerbart and mevonlerbart, given alone or together (called REGN-2Cat), to see if they help with cat allergy-related pink eye compared to a placebo. The drugs are given randomly in different groups.

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Placebo Group

Group I: REGN-2CatExperimental Treatment1 Intervention
Group II: MevonlerbartExperimental Treatment1 Intervention
Group III: FreneslerbartExperimental Treatment1 Intervention
Group IV: Matching placeboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Regeneron Pharmaceuticals

Lead Sponsor

Trials
690
Recruited
948,000+
Founded
1988
Headquarters
Tarrytown, USA
Known For
Precision medicine
Top Products
Dupixent, EYLEA, Libtayo, Praluent
Leonard Schleifer profile image

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos profile image

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School